RLYB
Rallybio Corporation
NASDAQ · Healthcare · Biotechnology · US
$16.93
+0.30%Margins
Gross margin
-1107.6%
EBITDA margin
4174.1%
EBIT margin
-3672.3%
Net margin
7051.2%
FCF margin
4077.4%
48.2%
Return on equity
46.5%
Return on assets
-25.1%
Return on invested capital
0.01x
Asset turnover
$26.3M
Cash from operations
$17
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026